ROSALIND ADVISORS INC
Q2 2024 Form 13-F

TORONTO, ONTARIO, CANADA
CIK 0001622627 · Institutional investment manager
$130.0M Reported Value Total
Reported value
$130.0M
Quarter over quarter
-10.3%
Holdings
35
Top-10 concentration
59.8%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2024 13F record

Q2 2024 13F filing summary

Q2 2024 Form 13F portfolio summary
Period of report June 30, 2024
Filed July 12, 2024
Form 13F-HR
Reported value $130.0M
Positions 35
Change in reported value +21.4%
New positions 5
Exited positions 1
Position turnover 16.7%
Top-10 concentration 59.8%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
35 $311.9M
Q2 2026 13F
Filed Aug 14, 2026
29 $269.2M
Q1 2026 13F
Filed May 14, 2026
32 $248.9M
Q4 2025 13F
Filed Feb 12, 2026
29 $284.5M
Q3 2025 13F
Filed Nov 13, 2025
29 $292.6M
Q2 2025 13F
Filed Aug 14, 2025
29 $210.9M
Q1 2025 13F
Filed May 14, 2025
31 $205.6M
Q4 2024 13F
Filed Feb 11, 2025
28 $195.6M
Q3 2024 13F
Filed Oct 30, 2024
29 $156.2M
Q2 2024 13F
Filed Jul 12, 2024
35 $130.0M
Q1 2024 13F
Filed Apr 25, 2024
31 $107.0M
Q4 2023 13F
Filed Feb 14, 2024
27 $121.4M

Top 20 holdings · Q2 2024

Largest Q2 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 DCTH DELCATH SYSTEMS, INC. $15.5M 11.95%
2 MYO MYOMO INC $8.6M 6.58%
3 MDWD MEDIWOUND LTD $8.0M 6.13%
4 OPTN OPTINOSE INC $7.8M 6.04%
5 ABEO ABEONA THERAPEUTICS-NEW $7.4M 5.71%
6 XERS XERIS BIOPHARMA HLDGS INC $7.0M 5.4%
7 CLRB CELLECTAR BIOSCIENCES INC $6.8M 5.2%
8 NSPR INSPIREMD INC $6.3M 4.83%
9 CYBN CYBIN INC $5.2M 4.02%
10 OCUL Ocular Therapeutix, Inc $5.1M 3.95%
11 ABVX ABIVAX SA $5.0M 3.85%
12 PROF PROFOUND MEDICAL CORP $4.5M 3.44%
13 CMPS COMPASS PATHWAYS PLC $4.4M 3.41%
14 TRVI TREVI THERAPEUTICS INC $4.1M 3.19%
15 KALV KALVISTA PHARMACEUTICALS INC $4.0M 3.06%
16 VRDN VIRIDIAN THERAPEUTICS INC $3.9M 3.0%
17 VRNA VERONA PHARMA PLC $3.6M 2.78%
18 CLSD CLEARSIDE BIOMEDICAL INC $3.4M 2.59%
19 OTLK OUTLOOK THERAPEUTICS INC $3.3M 2.56%
20 VERU VERU INC $2.3M 1.75%

Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings